Kaplan-Meier Curves of Progression-Free Survival (PFS) and Overall Survival (OS) Distributions after Vandetanib with Cetuximab and Irinotecan in Metastatic Colorectal Cancer Patients.

<p><b>A</b>, PFS distribution for all patients (n = 27). <b>B</b>, PFS distribution for patients with confirmed KRAS wild-type tumors (n = 20). <b>C</b>, PFS distribution for all patients (n = 27). <b>D</b>, PFS distribution for patients with confirmed KRAS wild-type tumors (n = 20).</p

Study CONSORT Flow Diagram.

<p>Study CONSORT Flow Diagram.</p

Pre-treatment values and fold-changes in plasma biomarkers after treatment with vandetanib and cetuximab (days 8 and 15) and with vandetanib, cetuximab and irinotecan (day 21, cycle 3 and cycle 5) in metastatic colorectal cancer patients.

<p>Data are shown as medians and interquartile ranges (in square brackets) compared to baseline levels. <i>P</i>-values are from the exact paired Wilcoxon test, before and after adjustment for multiple comparisons over time using the method of Genovese at al. VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; PlGF, placental growth factor; sVEGFR-1, soluble VEGF receptor-1; sVEGFR-2, soluble VEGF receptor-2; SDF-1α, stromal cell-derived factor-1-alpha; IL-6, interleukin-6; IL-8, interleukin-8; TNF-α, tumor necrosis factor-alpha.</p

Waterfall Plot.

<p>Best response analysis after vandetanib with cetuximab and irinotecan limited to patients with confirmed KRAS wild-type metastatic colorectal cancer and at least 1 restaging imaging scan.</p

Adverse Events (based on worse toxicity by patient).

*<p>includes magnesium, potassium, sodium and calcium changes.</p